Geron is a biopharmaceutical company focused on telomerase inhibition as a treatment approach in blood cancers. Its lead commercial product is imetelstat (RYTELO), approved for certain patients with lower-risk myelodysplastic syndromes who need transfusions. The company serves hematology specialists and patients with limited options in myelodysplastic disease and related myeloid malignancies.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 49 | — | -16.4 | — |
| Q3 2025 | 47.2 | — | -18.4 | — |
| Q4 2025 | 48 | — | -28.9 | — |
| Q1 2026 | 51.8 | — | -3.6 | — |
| Q2 2026 | 57.5 | 17.2% | -16.7 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Heartland Express, Inc. (HTLD), Camden National Corporation (CAC), D-Market Elektronik Hizmetler ve Ticaret A.S. (HEPS), Karat Packaging Inc. (KRT), Oxford Lane Capital Corp. (OXLC), Design Therapeutics, Inc. (DSGN)